Myeloma (MM1s), pancreas (ASPC-1) and colon (HCT 116) cancer cells were treated for 2 h with DNA damage response inhibitors (i.e. ATM inhibitor (KU-55933), DNA-dependent protein kinase catalytic subunit inhibitor (DNA-PK inhibitor II), and an alternative join repair inhibitor (PARP, NU1025)]. Here, PRKDC is linked to plasma cell myeloma.